Biogenesis is a technology company.
Biogenesis has raised $250K across 1 funding round.
Biogenesis has raised $250K in total across 1 funding round.
Biogenesis has raised $250K in total across 1 funding round.
Biogenesis's investors include Alumni Ventures, Ben Taft's Genius Ventures, General Catalyst, Kepler Operator’s Fund, Afraj Gill, Bianca Ambrosini.
BioGenesis Tech, Inc. is a patient-facing mobile app that integrates electronic medical records (EMR), genomic sequencing, nutritional and symptomatic data, and wearables to deliver AI-driven diagnostic and prognostic feedback based on evidence-based medicine.[1] Founded in 2022 in South San Francisco, California, it primarily targets expecting mothers with high-risk pregnancies—a underserved group despite their high needs—and has raised early funding from UCSC while building traction in healthcare AI, consumer genomics, and patient health records.[1]
The app solves the problem of fragmented health data by compiling comprehensive inputs into actionable insights, serving patients directly rather than healthcare providers. Early momentum includes a focused team and investor backing, positioning it for growth in personalized medicine amid rising demand for proactive maternal health tools.[1]
BioGenesis Tech, Inc. was founded in 2022 by Edward Fisher and Martin Michalko in South San Francisco.[1] Edward Fisher, with a B.A. in Economics & Data/Life Science from UCSC, shifted from clinical hematology pursuits and investment banking (including a summer analyst role at J.P. Morgan Chase) to entrepreneurship in medicine.[1] Martin Michalko, the CTO, is a scientist and MLOps engineer passionate about data science, biology, and medicine.[1]
The idea emerged from recognizing gaps in patient-centric health tech, particularly for high-risk pregnancies, where few solutions aggregate diverse data sources like EMRs, genomics, wearables, and symptoms. Early traction came via UCSC investment and a lean team focused on this niche, marking a pivotal shift toward AI-enabled personal health management.[1]
BioGenesis rides the wave of AI-powered personalized medicine and digital health for maternal care, where trends like wearable adoption and genomic accessibility are exploding amid post-pandemic focus on preventive care.[1] Timing is ideal: high-risk pregnancies affect millions globally, yet patient tools lag behind provider-centric systems, amplified by market forces like rising fertility tech investments and data privacy regulations favoring secure, consumer apps.
It influences the ecosystem by pioneering direct-to-patient AI aggregation, potentially accelerating adoption of multi-omics health platforms and inspiring similar tools for chronic conditions, while contributing to broader equity in underserved health segments like maternal health.[1]
BioGenesis is poised to scale its app through partnerships with wearables giants and EMR providers, expanding beyond maternal health into general consumer genomics as AI models mature.[1] Trends like real-world evidence integration and edge AI on devices will shape its path, potentially evolving it into a full-stack personal health OS with global reach. Its niche entry could amplify influence, humanizing tech for vulnerable patients and setting a benchmark for data-driven diagnostics in an increasingly proactive healthcare landscape—echoing its core mission to deliver comprehensive, life-impacting health insights.[1]
Biogenesis has raised $250K across 1 funding round. Most recently, it raised $250K Seed in October 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2023 | $250K Seed | Alumni Ventures, Ben Taft's Genius Ventures, General Catalyst, Kepler Operator’s Fund, Afraj Gill, Bianca Ambrosini |